反应详情

The title compound was prepared by procedure E using 7-chloro-2-(4-methoxy-3,5-dimethylphenyl)furo[3,2-b]pyridine (28.90 mg; 0.10 mmol; 1.00 eq.) instead of 7-chloro-2-(3,4,5-trimethoxyphenyl)furo[3,2-b]pyridine, and 4-methyl-1H-indol-5-ylamine (15.42 mg; 0.11 mmol; 1.05 eq.) instead of 6-amino-2,2-difluoro-4H-benzo[1,4]oxazin-3-one, and was obtained as a white solid (22 mg, 56%). (HPLC (method F): 99%, RT: 4.37 min); 1H NMR (500 MHz, DMSO-d6) δ [ppm] 11.15 (s, 1H), 8.51 (s, 1H), 7.94 (d, J=5.5, 1H), 7.54 (s, 2H), 7.38 (t, J=2.7, 1H), 7.30 (d, J=8.3, 1H), 7.25 (s, 1H), 7.00 (d, J=8.4, 1H), 6.52 (s, 1H), 6.14 (d, J=5.5, 1H), 3.69 (s, 3H), 2.35 (s, 3H), 2.25 (s, 6H); MS (m/z) 398 [M+H]+, RT: 4.2 min.